NCT00095628 · REGISTRY CONDITION SEARCH

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2017-03-06

This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses)

→

outcome · POSTED

Duration of Objective Response

→

outcome · POSTED

Number of Participants With Clinical and Objective Stable Disease

→

outcome · POSTED

Median Overall Survival of SB-715992

→

outcome · POSTED

Median Time to Progression

→

outcome · POSTED

1 Year Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients must have histologically or cytologically confirmed squamous cell carcinoma of the head and neck that is recurrent or metastatic; with the exception of the nasopharynx, all primary sites (including oral cavity, oropharynx, hypopharynx, and larynx) will be eligible; MedDRA disease terms: * Oral neoplasms NOS, 10031008 * Oropharyngeal cancer recurrent, 10031098 * Hypopharyngeal cancer recurrent, 10021044 * Laryngeal cancer recurrent, 10023828 * Maxillofacial sinus neoplasm, 10026956 * Head and neck, 90002024 * Patients may have had a maximum of one prior chemotherapy regimen for recurrent or metastatic disease; patients may enter this study and receive SB-715992 as their first-line therapy for recurrent and/or metastatic disease; prior platinum-based chemotherapy delivered concurrently with radiotherapy, or prior platinum-based induction chemotherapy, is allowed; there must be at least a 4 week interval between any chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy or surgery and study enrollment; exceptions may be made however, for low dose, non-myelosuppressive radiotherapy - please contact the Principal Investigator (Dr. E. Winquist) PRIOR to registration if questions arise about the interpretation of this criterion; for patients who received local therapy prior to study entry, there must be either progression of measurable disease documented within the treatment field, or must have measurable disease outside the treatment field prior to study entry * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral CT scan * Life expectancy of greater than 12 weeks. * ECOG performance status 0,1, or 2 * Leukocytes \>= 3,000/uL * Absolute neutrophil count \>= 1,500/uL * Platelets \>= 100,000/uL * Total bilirubin =\< 1.5 X institutional upper limit of normal * AST(SGOT)/ALT(SGPT) =\< 3.0 X institutional upper limit of normal (=\< 5.0 X if liver metastases) * Creatinine =\< 1.5 X institutional upper limit of normal * Peripheral neuropathy may be no greater than grade 1 * Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of SB-715992 will be determined following review of their use by the TREATING RESPONSIBLE investigator; patients receiving nonprohibited medications or substances known to interact with CYP450 isoenzymes may be eligible but should be monitored carefully; questions about eligibility related to concommitant use of medications should be discussed with the Principal Investigator * HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study * Patients requiring oral anticoagulants (coumadin, warfarin) are eligible provided there is increased vigilance with respect to monitoring INR. If medically appropriate and treatment available, the investigator may also consider switching these patients to LMW heparin, where an interaction with SB-715992 is not expected * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients with non-squamous cell carcinomas of the head and neck or nasopharyngeal cancer * Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from AEs due to agents administered more than 4 weeks earlier * Patients may not have received any other investigational agents within 28 days of study entry * Patients may not receive other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study * The following lists of medications/substances are moderate to significant inhibitors/inducers of CYP3A4 that, if administered concomitantly with SB-715992, may alter study drug exposure; the use of these medications/substances within 14 days (\>= 6 months for amiodarone) prior to the administration of the first dose of SB-715992 through discontinuation from the study is prohibited * Inhibitors of CYP3A4: * Antibiotics: clarithromycin, erythromycin, troleandomycin * Antifungals: itraconazole, ketoconazole, fluconazole (doses \> 200 mg/day), voriconazole * Antidepressants: nefazodone, fluovoxamine * Calcium channel blockers: verapamil, diltiazem * Miscellaneous: amiodarone\*, grapefruit juice, bitter orange * Use of amiodarone within 6 months prior to the administration of the first dose of SB-715992 is prohibited * Inducers of CYP3A4: * Anticonvulsants: phenytoin, carbamazepine, Phenobarbital, oxcarbazepine * Antibiotics: rifampin, rifabutin, rifapentine * Miscellaneous: St. John's wort, modafinil * Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * History of allergic reactions attributed to compounds of similar chemical or biologic composition to SB-715992 * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because SB-715992 is a mitotic inhibitor with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with SB-715992, breastfeeding should be discontinued if the mother is treated with SB-715992
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: ispinesib
Other: laboratory biomarker analysis
Other: pharmacological study
label
Treatment (ispinesib)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (ispinesib)
description
Given IV
name
ispinesib
other Names
CK0238273
SB-715992
type
DRUG
arm Group Labels
Treatment (ispinesib)
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER
arm Group Labels
Treatment (ispinesib)
description
Correlative studies
name
pharmacological study
other Names
pharmacological studies
type
OTHER

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 21
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
Overall survival is defined as the time from enrolment until death due to any cause. The Kaplan-Meier method was used to estimate overall survival.
measure
1 Year Overall Survival
time Frame
12 months

primary Outcomes

description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesion
measure
Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses)
time Frame
Up to 18 months

secondary Outcomes

description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesion
measure
Duration of Objective Response
time Frame
Up to 18 months
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease.
measure
Number of Participants With Clinical and Objective Stable Disease
time Frame
Up to 18 months
description
Overall survival is defined as the time from enrolment until death due to any cause. The Kaplan-Meier method was used to estimate overall survival.
measure
Median Overall Survival of SB-715992
time Frame
Up to 18 months
description
Time to progression (TTP) is defined as the time from enrolment onto the study until progression or death. The Kaplan-Meier method was used to estimate TTP.
measure
Median Time to Progression
time Frame
Up to 18 months

Full study description

brief Summary: This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.
detailed Description: PRIMARY OBJECTIVES: I. To determine the antitumor activity of SB-715992 in recurrent and/or metastatic squamous cell carcinoma of the head and neck using objective response rates (partial and complete responses). SECONDARY OBJECTIVES: I. To determine the duration of objective response, rate and duration of stable disease, progression-free, median and overall survival rates of SB-715992 in recurrent and/or metastatic squamous cell carcinoma of the head and neck. II. To document the safety and tolerability of SB-715992 in recurrent and/or metastatic squamous cell carcinoma of the head and neck. III. To characterize the population pharmacokinetic (PK) parameters of SB-715992 including an assessment of significant covariates on SB-715992 PK and an assessment of the potential relationships between the pharmacokinetics of SB-715992 and relevant safety and efficacy endpoints. OUTLINE: This is an open-label, nonrandomized, multicenter study. Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2c17228cd4ecc208093c
requested nct id
NCT00095628
primary nct id
NCT00095628
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
payload sha256
c52e9a7cf6a1c1b2614709c12e4f56cddc91463f73f163625d9f50e72829ab3a
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2c17228cd4ecc208093c
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00095628
occurrences
context exact
NCT00095628
end
11
exact text
NCT00095628
start
0
offset unit
unicode_code_points
query cond
Metastatic Squamous Neck Cancer With Occult Primary
query disease state id
ds-metastatic-squamous-neck-cancer-with-occult-primary
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
source json pointer
/studies/15/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c68556ac31da0493270f151fc5788adb1db667b941b16dfed10445a5b9f6e670
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-51dd2fc0bffcd7967cc6
requested nct id
NCT00095628
primary nct id
NCT00095628
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
13e0a8897cfc93db8b1df5855f0ba9735092c16c7cf5c997b6937ca1220758d0
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-51dd2fc0bffcd7967cc6
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00095628
occurrences
context exact
NCT00095628
end
11
exact text
NCT00095628
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/69/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c68556ac31da0493270f151fc5788adb1db667b941b16dfed10445a5b9f6e670
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-bcc430992a834978d421
requested nct id
NCT00095628
primary nct id
NCT00095628
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
421adcf196274d8790813d87646147c3d3c92c86fd1709a38cd8dd333f59bba0
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-bcc430992a834978d421
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00095628
occurrences
context exact
NCT00095628
end
11
exact text
NCT00095628
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/55/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c68556ac31da0493270f151fc5788adb1db667b941b16dfed10445a5b9f6e670
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-ed5ae1bceb3c6917c9ec
requested nct id
NCT00095628
primary nct id
NCT00095628
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
payload sha256
d746d229465f393a0379f9877f995c00b26dc1bb5bd9b93379447352ce84e54b
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-ed5ae1bceb3c6917c9ec
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00095628
occurrences
context exact
NCT00095628
end
11
exact text
NCT00095628
start
0
offset unit
unicode_code_points
query cond
Salivary Gland Cancer
query disease state id
ds-salivary-gland-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
source json pointer
/studies/33/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c68556ac31da0493270f151fc5788adb1db667b941b16dfed10445a5b9f6e670
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice